#Juvenile Idiopathic Arthritis Treatment Market Forecast | Explore Tumblr posts and blogs

communicationblogs · 2 months ago

Text

Tumor Necrosis Factor Inhibitor Drugs Market — Forecast(2024–2030)

Tumor Necrosis Factor (TNF) Inhibitor Drugs Market size was valued at USD 248.8 Billion in 2023 and is projected to reach USD 13019.65 Billion by 2030, growing at a CAGR of 0.64% during the forecast period 2024–2031.

Market Drivers

Rising Prevalence of Autoimmune Diseases: The demand for TNF inhibitor drugs is growing due to the increasing incidence of autoimmune conditions such as psoriasis, Crohn’s disease, ankylosing spondylitis, and rheumatoid arthritis. These drugs help manage symptoms, reduce inflammation, and slow disease progression in affected individuals.

Request Sample

Aging Population: The global aging population is more susceptible to autoimmune and chronic inflammatory diseases, boosting the need for TNF inhibitor therapies. As the population continues to age, the prevalence of these conditions is expected to rise, driving greater demand for TNF inhibitors.

Broadened Indications and Treatment Options: TNF inhibitors are being prescribed for an expanding range of inflammatory and immune-mediated disorders beyond rheumatoid arthritis and inflammatory bowel disease. This includes conditions like ulcerative colitis, juvenile idiopathic arthritis, and psoriatic arthritis, which contributes to increased adoption and market growth.

Effective Disease Management: TNF inhibitors have proven effective in alleviating symptoms, improving quality of life, and preventing joint damage in autoimmune disease patients. Their ability to manage chronic conditions and reduce inflammation addresses significant unmet medical needs.

Inquiry Before Buying

Advancements in Biotechnology and Drug Development: Innovations in immunology, molecular biology, and biotechnology are leading to the development of new TNF inhibitors with better tolerance, safety, and efficacy profiles. Additionally, the introduction of biosimilar TNF inhibitors provides more affordable treatment options, enhancing patient access.

Patient Preference for Biologic Therapies: Many patients favor biologic therapies, including TNF inhibitors, over traditional disease-modifying antirheumatic drugs (DMARDs) due to their targeted action, longer dosing intervals, and potential for improved outcomes. This preference fuels the market demand.

Increased Healthcare Expenditure: Rising healthcare spending, particularly in developed countries, facilitates access to TNF inhibitor medications. Government healthcare programs, private insurance, and reimbursement policies help make these treatments more affordable and accessible, supporting market growth.

Support from Clinical Guidelines and Evidence: Strong clinical data and treatment guidelines reinforce the use of TNF inhibitors, boosting physician confidence and patient acceptance. Evidence-based recommendations guide the adoption and prescribing practices of these therapies.

Advances in Personalized Medicine: Developments in pharmacogenomics and personalized medicine allow for customized treatment plans based on individual patient needs, condition severity, and therapy response. This personalization enhances treatment efficacy and patient satisfaction, driving market demand.

Market Restraints

High Treatment Costs: TNF inhibitors are often expensive, which can be a barrier to access for patients, healthcare systems, and payers, especially in regions with limited healthcare resources or inadequate insurance coverage. The high cost may lead to underutilization of these therapies.

Buy Now

Safety Concerns and Side Effects: Despite their effectiveness, TNF inhibitors can be associated with risks such as infections, cancer, infusion reactions, and other side effects. Safety concerns may deter both patients and healthcare providers from initiating or continuing treatment, particularly in high-risk groups.

Immunogenicity and Loss of Response: Over time, patients may develop antibodies against TNF inhibitors, leading to treatment failure and reduced efficacy. This immunogenicity can necessitate dose adjustments, alternative therapies, or combination treatments to maintain disease control.

Limited Efficacy in Certain Populations: TNF inhibitors may be less effective in patients with severe or treatment-resistant diseases, those with concurrent health conditions, or individuals with specific genetic profiles. Limited response in these populations can impact the perceived value of these therapies.

Availability of Alternative Therapies: The presence of alternative treatments, including non-pharmacological options, tailored synthetic DMARDs, and other biologic drugs, can pose competition to TNF inhibitors. This competition may affect their market share and acceptance.

Regulatory and Reimbursement Challenges: Various regulatory hurdles, market access barriers, and reimbursement constraints can restrict patient access to TNF inhibitors. Delays in payer policies, formulary restrictions, and regulatory approvals may hinder market penetration.

Impact of Patent Expirations and Biosimilar Competition: As patents for branded TNF inhibitors expire, biosimilars enter the market, increasing competition and driving down prices. This competition can affect the pricing, profitability, and market share of original TNF inhibitor products.

Chronic Nature of Autoimmune Disorders: Autoimmune disorders treated with TNF inhibitors require long-term management, which can be challenging for patients. Continuous treatment adherence, regular monitoring, and follow-up are necessary, which can impact patient compliance and healthcare resource utilization.

Challenges with Drug Administration: TNF inhibitors are often administered intravenously or via subcutaneous injection, which can be uncomfortable and logistically challenging for patients. Issues like injection site reactions, complex dosing schedules, and the need for medical resources can affect treatment adherence and patient satisfaction.

Market Segmentation

The Global TNF Inhibitor Drugs Market is segmented based on:

Drug Type: Includes monoclonal antibodies, recombinant proteins, and biosimilars.

Application: Encompasses rheumatoid arthritis, psoriasis, inflammatory bowel disease, ankylosing spondylitis, juvenile idiopathic arthritis, and other inflammatory and immune-mediated conditions.

Distribution Channel: Comprises hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies.

Geography: Covers regions such as North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

#reseach marketing #marketing #digital marketing #Tumor #brain tumor #three tumors #health & fitness #healthcare #healthylifestyle

0 notes

healthcareanna · 2 months ago

Text

Biosimilars Market Size, Trends, Growth Analysis 2032

Biosimilars Market Overview

An integral component of the Biosimilars Market is the emergence of follow-on biologics. These biologics, which closely resemble existing biologic drugs, offer additional options for patients and healthcare providers. Follow-on biologics undergo rigorous testing to demonstrate similarity to the reference product, ensuring interchangeability and therapeutic equivalence. With their introduction, follow-on biologics stimulate competition in the biopharmaceutical industry, driving down prices and promoting innovation. As the demand for cost-effective biologic therapies continues to grow, the Biosimilars Market stands to benefit from the availability and acceptance of follow-on biologics, expanding treatment options and improving patient outcomes.

According to Market Research Future (MRFR), the biosimilars market insights was valued at USD 29.7 billion in 2023 and is projected to grow from USD 36.79 Billion in 2024 to USD 161.95 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 20.35% during the forecast period (2024 - 2032).

Biosimilars Market: Latest News and Developments

The FDA has approved the first Humira biosimilar. Adalimumab-bwwd (Cyltezo), a Humira biosimilar, received FDA approval in January 2023 for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.

Rising use of biosimilars in the treatment of cancer. A growing number of biosimilars are being used to treat cancer. The FDA authorised filgrastim-sndz (Zarxio), pegfilgrastim-jmdb (Onpro), and trastuzumab-dkst (Herzuma) as three biosimilars for the treatment of cancer in 2022.

Market Segmentation

Biosimilars industry can be considered with respect to product, applications, and end users.

The products based on which the market has been split into are recombinant glycosylated proteins, recombinant peptides, and recombinant non-glycosylated proteins. Recombinant non-glycosylated proteins are the biggest segment in the global market, thanks to the soaring cases of chronic disorders ranging from growth hormone deficiency to diabetes. As a result, recombinant non-glycosylated proteins are therapeutically used as they are readily available and are cost-effective.

Application-wise, the biosimilars market caters to chronic diseases, oncology, blood disorders, autoimmune diseases, infectious diseases, growth hormone deficiency, and more. Blood disorders have emerged as the top segment, as a result of the rising burden of the condition worldwide and the increased use of biosimilars by virtue of their low cost and the overall reduction in the treatment cost.

Major end users in the global market are hospitals and clinics as well as research institutes. Hospital and clinics are healthcare settings where treatment options and skilled professionals are easily available, and therefore, have emerged as the leading segment in the global industry.

Regional Status

Europe, MEA or Middle East & Africa along with the Americas, APAC or Asia Pacific are the primary markets for biosimilars.

Europe has taken the lead in the global market, as the region houses a vast elderly pool, with close to one fifth of the overall EU population aged more than 65 years. This has given way to several lifestyle-related disorders such as oncology, autoimmune diseases, diabetes, to name a few. Presumably, the scenario has raised the demand for biosimilars and can mean higher market growth over the next few years. In addition to this, numerous blockbuster biologics are on track to lose patent in the coming years, which should present lucrative opportunities to the biosimilar manufacturers.

The North American market displays a bright outlook and can emerge quite lucrative in the coming years, in view of the surging burden of chronic ailments in Canada and the United States. The rising spending on research activities by the healthcare agencies also fuels the market expansion in the region. Favorable reimbursement landscape in the region, especially in the US, encourages healthy competition as it results in lower incentives for the players to compete based on price.

The APAC market is slated to witness considerable growth, with China, South Korea and India offering a host of lucrative opportunities for drug development as well as commercialization. These are generics-driven countries and are known for frequently launching new and advanced manufacturing platforms, which has brought down the costs associated with biosimilar production. In the coming few years, majority of the patent expiries is touted to be in biosimilars, which is deemed as a profitable aspect by leading manufacturers and can translate into substantial market growth.

Eminent Vendors

Top global key players listed by biosimilars market outlook report include Stada Arzneimittel AG (Germany), Teva Pharmaceuticals (Israel), Biocon (India), Pfizer (US), Sandoz International (Germany), Eli Lily & Company (US), Actavis, Inc. (US), Dr. Reddy’s Laboratories (India), Cipla Ltd (India), Amgen, Inc. (US), Samsung Biologics (South Korea), Hospira Inc.(US), Mylan, Inc.(US), Celltrion (South Korea), to mention a few.

More Related Trending Topics

Medical Foods market

Insomnia market

Blockchain Technology in Healthcare market

Drug Device Combination market

Prefilled Syringes market

#healthcare #medical #health #medical devices #Biosimilars Market Size

0 notes

dbmr-blog-news · 6 months ago

Text

#Rheumatoid Arthritis Treatment Market

0 notes

alicesara611 · 1 year ago

Text

Forecasting Success: Examining the Humira Market's Trajectory Over By 2023 to 2030

The global humira market is expected to reach US$ 3871.4 million by 2030, at a CAGR of 25.9%. The market is driven by the increasing prevalence of inflammatory diseases, the aging population, and the rising demand for biologics, driven by factors such as an aging population, rising prevalence of chronic inflammatory diseases, and advancements in medical technology. However, the introduction of biosimilars, which are highly similar to Humira in terms of structure and function, is expected to disrupt the market dynamics.

In the realm of pharmaceuticals, Humira, a tumor necrosis factor (TNF) blocker, stands as a towering figure, having revolutionized the treatment of inflammatory conditions. Its efficacy and broad spectrum of applications have propelled it to the forefront of the healthcare industry, generating substantial revenue and garnering significant attention. However, as Humira's patent protection wanes, the market landscape is poised for a significant transformation, with the emergence of biosimilars and the potential for increased competition.

Get your Sample Report with Latest Market Information! https://absolutemarketresearch.com/Global-Humira-Market/1269/request-sample

The Humira market is poised for a period of significant change and evolution in the coming years. The emergence of biosimilars will undoubtedly reshape the market landscape, introducing new players and intensifying competition. While Humira is expected to maintain a strong position in the market, biosimilars are poised to capture a growing share, offering patients with more affordable treatment options. The Humira market will undoubtedly remain dynamic and evolving, presenting both challenges and opportunities for industry players.

Humira Market: Key Takeaways:

The global Humira market is expected to reach US$ 3871.4 million by 2030, growing at a CAGR of 25.9%.

The increasing prevalence of inflammatory diseases, such as rheumatoid arthritis, psoriatic arthritis, and Crohn's disease, is driving the growth of the Humira market.

The rising adoption of biosimilars is expected to put pressure on Humira's prices, but it is also expected to expand the market by making Humira more accessible to patients in developing countries.

The Asia-Pacific region is expected to be the fastest-growing market for Humira, driven by the increasing prevalence of inflammatory diseases and the growing adoption of biosimilars.

Humira Market Regional Outlook:

North America is the largest market for Humira, accounting for over 60% of the global market share in 2023.

Europe is the second-largest market for Humira, accounting for over 30% of the global market share in 2023.

The Asia-Pacific region is the fastest-growing market for Humira, due to the increasing prevalence of inflammatory diseases and the growing adoption of biosimilars.

Humira Market Key Players:

AbbVie

Amgen

Boehringer Ingelheim

Cadila Healthcare

Eisai

Torrent Pharmaceuticals

Humira Market Segmentation:

By Indication:

Rheumatoid Arthritis

Psoriatic Arthritis

Crohn's Disease

Ulcerative Colitis

Ankylosing Spondylitis

Hidradenitis Suppurativa

Juvenile Idiopathic Arthritis

By Type:

Humira Syringe

Humira Pen

By Dosage Strength:

40mg/0.4mlg

80mg/0.8mlg

20mg/0.2mlg

10mg/0.1mlg

By Drug Type:

Branded

Generics

By Route of Administration:

Parenteral

Oral

By Population Type:

Adults

Children

By End User:

Hospital/Clinical Laboratories

Physician Offices

Reference Laboratories

Other End Users

By Distribution Channel:

Direct Tender

Pharmacy

E-commerce

#Humira Market

0 notes

pharmaceuticals88 · 2 years ago

Text

Juvenile Idiopathic Arthritis Treatment Market Growing Massively by 2022-2027 Major Players Johnson & Johnson, Novartis, Bristol-Myers Squibb

The Juvenile Idiopathic Arthritis Treatment Market by 2029, exhibiting a CAGR of 8.2% during 2022-2029

Juvenile Idiopathic Arthritis Treatment Market Overview

The Juvenile Idiopathic Arthritis Treatment Market report is a comprehensive overview of the market, including a review of its major segments Juvenile Idiopathic Arthritis Treatment Market are developed after thorough primary and secondary studies. By speaking with industry experts and collecting their data, in-depth market data is produced. The report provides a thorough account of many market factors, including trends, segmentation, growth prospects, chances, difficulties, and competitive analyses.

Get a Sample copy of the report:

List of Key Players of Juvenile Idiopathic Arthritis Treatment Market Report:

Johnson & Johnson, Novartis, Bristol-Myers Squibb, Zydus Cadila, Takeda, Roche, Latona Life Sciences

Key Segments Covered in Juvenile Idiopathic Arthritis Treatment Market

By Type, it is segmented into

Surgical Treatment

Drug Treatment

By Application, it is segmented into

Hospital

Clinic

Diagnostic Laboratories

Competitive Landscape

Juvenile Idiopathic Arthritis Treatment Market are showing an increasing amount of interest in creating unique products. In addition, several companies are collaborating, merging, and acquiring one another. In the upcoming years, all of these initiatives are anticipated to drive the global Juvenile Idiopathic Arthritis Treatment Market to new heights.

The Juvenile Idiopathic Arthritis Treatment Market Regional Analysis Covers

– North America: United States, Canada, and Mexico. – South & Central America: Argentina, Chile, and Brazil. – Middle East & Africa: Saudi Arabia, UAE, Turkey, Egypt and South Africa. – Europe: UK, France, Italy, Germany, Spain, and Russia. – Asia-Pacific: India, China, Japan, South Korea, Indonesia, Singapore, and Australia.

Get in Touch with Us: - Phone No.+1 (704) 266-3234

Mail to: [email protected]

#Juvenile Idiopathic Arthritis Treatment Market Research #Juvenile Idiopathic Arthritis Treatment Market Forecast #Juvenile Idiopathic Arthritis Treatment Market Size #Juvenile Idiopathic Arthritis Treatment Market Share #Juvenile Idiopathic Arthritis Treatment Market Trends #Juvenile Idiopathic Arthritis Treatment Market Overview

0 notes

insightaceanalaytic-blog · 5 years ago

Text

GLOBAL ADALIMUMAB BIOSIMILAR MARKET

InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on Global Adalimumab Biosimilar Market Assessment – Revenue Forecast (Value & Volume), Installed Base, Historic Revenue and Forecast Till 2027 Adalimumab is a first humanized monoclonal antibody indicated for the treatment of various autoimmune diseases. Adalimumab is an anti-TNF (tumour necrosis factor) drug that block the action of TNF (tumour necrosis factor)to reduce the inflammation. It is prescribed for the treatment of diseases such as rheumatoid arthritis,ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and psoriasis. It was first discovered by “phage display” technique which was named D2E7. Furthermore, it experienced the various manufacturing process at BASF Bioresearch Corporation and developed by BASF Knoll. In December 2000, Abbott announced the acquisition of BASF Bioresearch Corporation. In January 2013, Abbott Laboratories separated its pharma business named as AbbVie Inc. which was further involved in development and commercializing activities. AbbVie marketed Adalimumab product under the trade name of Humira. It was approved by U.S. Food Drug and Administration (FDA) in 2008 and by European Medicines Agency in 2003.

#Market Assessment #Adalimumab

1 note · View note

pranalipawarshinde · 2 years ago

Text

Biosimilars Market to advance at a CAGR of 15.5% from 2022 to 2031

Biosimilars Market Outlook 2031

The global biosimilars market was valued at US$ 20.4 Bn in 2021

The global market is expected to advance at a CAGR of 15.5% from 2022 to 2031

The global biosimilars market is anticipated to reach more than US$ 85 Bn by the end of 2031

Report Ovreview: https://www.transparencymarketresearch.com/biosimilars-market.html

Overview of Biosimilars Market

Biosimilar can be defined as a biologic medical product, which is considered very similar to an already-approved biologic. These biosimilars are approved based on their efficacy, quality, safety, and the standards of pharmaceutical quality that apply to all biologic medicines.

Biosimilars are generic versions of biologics that have passed their patent expiration date. The global biosimilars market is expected to be driven by patent expiration of well-known biologics. Increase in approval and sales of biosimilars has led to a significant decline in sales of biologics that had a steady or growing demand.

The burden of chronic diseases has been rising across the globe. Increase in prevalence of chronic diseases can be largely ascribed to the aging population and changing lifestyle of the people. Diabetes, hypertension, stroke, respiratory diseases, oral diseases, obesity, arthritis, and cancer are some of the common chronic diseases. On the other hand, biosimilar monoclonal antibodies are being extensively used in the treatment of rheumatoid arthritis and cancer.

Request A Sample: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=118

Approvals of biosimilars have been increasing globally owing to changing regulations and rise in pressure on healthcare systems to facilitate treatment for all patients. Biosimilars or copy biologics are being increasingly adopted by physicians, authorities, and patients, owing to the much-needed improvements in the access to therapeutically viable options for the treatment of various diseases. Companies are increasing the production of biosimilar medicines, oncology biosimilars, and Remicade biosimilars to broaden their revenue streams.

High Prevalence of Chronic Diseases and Rise in Number of Cancer Patients to Boost Biosimilars Market

Rise in prevalence of chronic diseases is augmenting the global market. Biosimilar drugs are becoming increasingly popular across the world because of their cost-effectiveness. Increase in cancer patients and chronic disease cases; and growth in geriatric population are projected to fuel the demand for biosimilars during the forecast period.

Over half of the population of the U.S. is likely to suffer from at least one chronic disease during their lifetime. According to the WHO, chronic disease prevalence is expected to rise by 57% by 2020. Rapid population growth in emerging markets is expected to drive the prevalence of chronic diseases.

Enquiry Before Buying: https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=118

Cancer is the second leading cause of death globally, with over 70% of deaths occurring in low- and middle-income countries. The incidence of cancer increases with age, most likely due to the rise in risk of specific cancers as people get older. Growth in pipeline of biosimilar drugs for the treatment of chronic diseases is projected to propel the global biosimilars market in the next few years. ABRILADA, a biosimilar to Humira, was approved by the U.S. Food and Drug Administration (FDA) in November 2019 for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis, and plaque psoriasis.

Changing Government Regulations to Augment Demand for Recombinant Non-glycosylated Protein Products

In terms of product, the recombinant non-glycosylated proteins segment held a relatively large market share in 2021. The segment has been split into insulin, granulocyte colony stimulating factor, recombinant human growth factor, and interferons.

Recombinant non-glycosylation involves the production of active substances in bacteria, which results in non-glycosylation, allowing the active substance to remain biologically active. Growth of the segment can be attributed to the rise in the prevalence of chronic diseases, which require recombinant non-glycosylated proteins biosimilars for treatment. Additionally, changing regulations and increase in focus of governments on the approval of biosimilars are anticipated to drive the recombinant non-glycosylated proteins segment during the forecast period.

Request Report Methodology: https://www.transparencymarketresearch.com/sample/sample.php?flag=RRM&rep_id=118

Advancements in Biomedical Technology to Drive Oncology Treatments

Based on indication, the oncology segment held large revenue share of the global biosimilars market in 2021. Growth in prevalence of cancer and increase in the number of ongoing studies in the biosimilars filed across the world are likely to augment the segment during the forecast period.

Biologics are a broad category of products that include blood and blood components, vaccines, hormones, and allergens (anti-allergy medications). Monoclonal antibodies are important biologics; these are used to treat a range of diseases, including breast cancer, lymphoma, rheumatoid arthritis, psoriasis, ulcerative colitis, and Crohn's disease.

Advancements in biomedical technology have resulted in an increase in commercialization of biologics in the last few decades. This has improved cancer care. Cancer treatment is expensive; therefore, development of a biosimilar product with comparable clinical efficacy has led to lower healthcare costs and improved access to care. Hence, the oncology segment is expected to account for significant share of the market during the forecast period.

Regional Outlook of Global Biosimilars Market

Europe held more than 45% share of the global biosimilars market in 2021. It is projected to be a highly lucrative region of the global market, with high market attractiveness index, during the forecast period.

The biosimilars market in Europe is the largest in the world, accounting for roughly 60% of the global biosimilars market and growing steadily year after year. As of October 2019, 54 biosimilars of 15 originator biological medicines were approved for marketing in Europe. Countries in Europe provide valuable examples of different approaches to biosimilars policy, led by their large biosimilars markets and diverse healthcare systems.

Ask References: https://www.transparencymarketresearch.com/sample/sample.php?flag=ARF&rep_id=118

Biosimilars sales reflect Europe's legislative and regulatory leadership in the market. The biosimilars markets in the region is more mature than that in the U.S. However, opportunities for biosimilars companies in Europe are limited due to lower overall spending on biologicals.

Europe has set the standard, approving more treatments than any other continent. Currently, biosimilars account for 10% of the total biologics market in the region, with a majority (7%) occurring in the past five years. The percentage is significantly higher in terms of volume, reflecting the steadily increasing level of revenue savings as a result of the rise in biosimilars competition and penetration. More than 60 biosimilars have been approved for use in the European Union (EU) to date, with several more being evaluated. Therefore, the biosimilars market in Europe is expected to grow at a significant pace during the forecast period.

Analysis of Key Players in Biosimilars Market

The global biosimilars market is consolidated, with a small number of leading players accounting for a relatively large share. Most of the companies are making significant investments in research & development activities. Diversification of product portfolio and mergers & acquisitions are important strategies adopted by key players in the global biosimilars market. Pfizer, Inc., Intas Pharmaceuticals Ltd., Biocon, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (A Novartis Division), Celltrion, Inc., Amgen, Inc., STADA Arzneimittel AG, and Apotex, Inc. are the prominent players operating in the global biosimilars market.

More Trending Reports by Transparency Market Research:

Atrial Fibrillation Market: https://www.transparencymarketresearch.com/atrial-fibrillation-market.html

Insulin Market: https://www.transparencymarketresearch.com/insulin-market.html

Ostomy Drainage Bags Market: https://www.transparencymarketresearch.com/ostomy-drainage-bags-market.html

Biosimilars Market: https://www.transparencymarketresearch.com/biosimilars-market.html

Cat Allergy in Humans Market: https://www.transparencymarketresearch.com/cat-allergy-in-humans-market.html

Dermal Filler Market: https://www.transparencymarketresearch.com/us-dermal-filler-market.html

Particle Therapy Market: https://www.transparencymarketresearch.com/particle-therapy-market.html

Physician Dispensed Cosmeceuticals Market: https://www.transparencymarketresearch.com/physician-dispensed-cosmeceuticals-market.html

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports. For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit Bhisey Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Website: https://www.transparencymarketresearch.com Blog: https://tmrblog.com Email: [email protected]

0 notes

leftcomputerpost · 3 years ago

Text

Juvenile Idiopathic Arthritis Diagnostics Market Is Set to Experience Revolutionary Growth by 2028

Juvenile Idiopathic Arthritis Diagnostics Market Overview

Arthritis is a very common disease but it is not well understood yet. Arthritis is basically joint pain or joint disease. Basically Juvenile idiopathic arthritis or juvenile rheumatoid arthritis is the common inflammatory arthritis of childhood and Common symptom of Juvenile idiopathic arthritis is musculoskeletal pain. Juvenile idiopathic arthritis is mostly affected to under age 17 children. Reorganization of Juvenile idiopathic arthritis is rare but treatable causes, including inflammatory, malignant and infectious etiologies. Juvenile idiopathic arthritis is present in both HLA and non-HLA gene associations play a role in its development, and susceptibility genes shared with other autoimmune disease conditions that have been identified. Complications of Juvenile idiopathic arthritis can be either articular or extra-articular. One of the most common diseases found in children is inflammatory eye disease which is anterior uveitis that is affecting up to 30% of children with Juvenile idiopathic arthritis. Symptoms such as Joint pain, swelling loss of appetite, rash, and fever are being observed.

Juvenile Idiopathic Arthritis Diagnostics Market: Market Dynamic

Rising demand of Juvenile Idiopathic Arthritis Diagnostics is due to increasing the prevalence rate of Juvenile Idiopathic arthritis such as Oligoarthritis, Polyarticular arthritis, rheumatoid factor negative, Psoriatic arthritis, Enthesitis-related arthritis and the increasing demand of undifferentiated arthritis. Increasing morbidity caused due to Juvenile Idiopathic Arthritis Diagnostics is also a factor driving the rapid advancement of technology demand for Juvenile Idiopathic Arthritis Diagnostics across the globe. Some key factors such as raising awareness of Juvenile Idiopathic Arthritis disease and patient education program that are conducted by government and companies for better knowledge about these diseases is likely to drive the growth of Juvenile Idiopathic Arthritis Diagnostics market. Initial diagnosing of Juvenile Idiopathic Arthritis Diagnostics consider the first signs of arthritis and that may be ore wrist, finger, or knee and iris inflammation with or without active joint symptoms in any type of Juvenile Idiopathic Arthritis. However, Juvenile Idiopathic Arthritis Diagnostics is too difficult and no single test and limited availability of test restraints the growth of Juvenile Idiopathic Arthritis Diagnostics market. Due to its increasing high demand and offers the best chance of curing the disease Juvenile Idiopathic Arthritis Diagnostics market is expected to grow for the forecast period.

Juvenile Idiopathic Arthritis Diagnostics Market: Overview

Global Juvenile Idiopathic Arthritis Diagnostics market has witnessed growth due to expanding demand for diagnostics and early detection of diseases. The global market Juvenile Idiopathic Arthritis Diagnostics is predicted to boost its expansion owing to the demand for understanding the pathogenesis of Juvenile Idiopathic Arthritis diseases. The ability of Juvenile Idiopathic Arthritis Diagnostics to improve treatment and reduce healthcare costs and that potentially drive the market of Juvenile Idiopathic Arthritis Diagnostics in the near future. Discovery of new Clinical evaluation and increased focus by the manufacturer to develop test creates huge opportunities for the developing Juvenile Idiopathic Arthritis Diagnostics for patients. Based on the diagnosing test, Juvenile Idiopathic Arthritis Diagnostics market has been segmented into Rheumatoid factor (RF), antinuclear antibodies, ant cyclic citrullinated peptide antibody, and HLA-B27 tests and others. Oncology segment holds a maximum share of global Juvenile Idiopathic Arthritis Diagnostics market on the basis of end user, Diagnostic Laboratories accounts for the maximum share owing to increased demand of Juvenile Idiopathic Arthritis diagnosing

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-8456

Juvenile Idiopathic Arthritis Diagnostics Market Insights, Forecast to 2026: Regional Outlook

In the terms of regional and geographical perspective, the global Juvenile Idiopathic Arthritis Diagnostics market is categorized into five key regions: North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. In terms of revenue, North America is expected to account for the largest share in the forecast period in the Juvenile Idiopathic Arthritis Diagnostics market owing to higher expenditure on research and development as well as presence of higher demand from the end users. Europe is expected to be the second leading regions in terms of revenue in Juvenile Idiopathic Arthritis Diagnostics market over the forecast period due to increasing number of manufacturers and advance research, high prevalence of chronic disease and improving healthcare infrastructure. Middle East & Africa Juvenile Idiopathic Arthritis Diagnostics market is expected to register slow growth because of lack of awareness and less expenditure spent on healthcare and research.

Juvenile Idiopathic Arthritis Diagnostics Market Insights, Forecast to 2026: Key Player

The global Juvenile Idiopathic Arthritis Diagnostics Market registers presence of large number of domestic manufacturers. Examples of some of the key players operating in the global Juvenile Idiopathic Arthritis Diagnostics Market are Johnson & Johnson Services, Inc., Novartis International AG, Bristol-Myers Squibb, Zydus Cadila, Takeda Pharmaceutical Company Limited, Genentech, Inc., Latona Life Sciences., and others.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

The report covers exhaustive analysis on:

Juvenile Idiopathic Arthritis Diagnostics Market Segments

Juvenile Idiopathic Arthritis Diagnostics Market Dynamics

Juvenile Idiopathic Arthritis Diagnostics Market Size

Supply & Demand

Current Trends/Issues/Challenges

Competition & Companies involved

Technology

Value Chain

Regional analysis includes

North America (U.S., Canada)

Latin America (Mexico, Brazil)

Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)

Eastern Europe (Russia, Poland, Rest Of Eastern Europe)

Asia Pacific Excluding Japan (China, India, Australia & New Zealand)

Japan

Middle East and Africa (GCC, S. Africa, Rest Of MEA)

For any queries linked with the report, ask an analyst >> https://www.futuremarketinsights.com/ask-question/rep-gb-8456

About FMI: Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us: Mr. Debashish Roy Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A, Jumeirah Lakes Towers, Dubai, United Arab Emirates MARKET ACCESS DMCC Initiative For Sales Enquiries: [email protected] For Media Enquiries: [email protected] Website: https://www.futuremarketinsights.com

0 notes

healthcare-market · 3 years ago

Text

Immunology Biosimilars Market Size, Analysis and Forecast up to 2024

A biosimilar medicine possesses similar pharmacokinetic and mode of action as an original biological medicine that has already been approved for therapeutic use. Biosimilars are made from a living organism such as bacteria and yeast or can also be derived from small molecules such as human insulin, erythropoietin, and monoclonal antibodies via recombinant DNA and gene expression technologies. Biosimilars are developed only when original biological medicines are commercially expired and therefore are known as follow on biologics or subsequent entry biologics. Biosimilars are used for autoimmune indications such as rheumatoid arthritis (RA) and ulcerative colitis. Tumor necrosis factor is a chemical produced by the immune system that causes inflammation in the body.

Read Report Overview: https://www.transparencymarketresearch.com/immunology-biosimilars-market.html

Immunology biosimilar drugs are used to treat inflammatory conditions such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, juvenile arthritis, Crohn’s disease, ulcerative colitis, psoriasis, and hidradinitis suppurativa. These drugs are able to reduce inflammation and stop disease progression. The market is expected to grow during the forecast period due to rise in prevalence of chronic diseases, autoimmune diseases, lower cost of drugs compared to branded drugs, and rise in incidence of cancer. According to the World Health Organization, cancer is one of the leading causes of morbidity and mortality across the world, with approximately 14 million new cases in 2012. The number of new cases is expected to rise by about 70% over the next two decades. Developing a new biological medicine can incur cost up to US$ 1.2 Bn that is also associated with a high risk of research and development failure. However, the overall cost and research and development risk with biosimilars and biosuperiors are less than the original biologics. By some estimates, from development to approval, a biosimilar could incur cost up to US$ 75 Mn to US$ 250 Mn. On account of a requisite of lower investment, several pharmaceutical and biopharmaceutical companies are striving to enter the biosimilars and biosuperiors market.

Request a Sample of Immunology Biosimilars Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=39479

The global immunology biosimilars market can be segmented based on disease indication, distribution channel, and region. In terms of disease indication, the market can be categorized into plaque psoriasis, arthritis, Crohn’s disease, and others. Arthritis can be further segmented into rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and juvenile idiopathic arthritis. Based on distribution channel, the global immunology biosimilars market can be classified into hospital pharmacies, retail pharmacies, and online pharmacies.

Enquiry before Buying Immunology Biosimilars Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=39479

Geographically, the global immunology biosimilars market can be segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2016. Usage of immunology biosimilars is high in North America primarily due to steady approval for new indications and research undertakings, and increasing geriatric population. According to the Immune Deficiency Foundation, currently around 55,000 people in the U.S. with antibody deficiency receive primary immunodeficiency diseases treatment. Expected launch of immunology biosimilars drugs that are presently in clinical trials in the U.S. during the forecast period is likely to boost market growth. Europe is expected to be the second largest market in terms of revenue and growth of the market in the region can be attributed to availability of several immunology biosimilar drugs such as Rituxan, Humira, Enbrel, and others. The market in Asia Pacific is expected to register high growth from 2017 to 2025 due to development of health care infrastructure, high disposable income, rise in health and hygiene related awareness, large untapped market base, and economic development.

Pre-book Immunology Biosimilars Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=39479&ltype=S

Key players operating in the global immunology biosimilars market include Novartis AG, Amgen, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., STADA Arzneimittel AG, Mylan N.V., and PRA Health Sciences.

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/inoculation-drives-to-attract-considerable-growth-for-the-disposable-syringes-market-auto-disposable-syringes-to-paint-bold-strokes-of-growth-tmr-301325488.html

https://www.prnewswire.com/news-releases/valuation-in-geriatric-medicines-market-to-reach-us-1142-8-bn-by-2027--use-in-managing-cardiovascular-diseases-spurs-growth-tmr-301331572.html

https://www.prnewswire.com/news-releases/asia-pacific-to-emerge-as-a-champion-growth-generating-region-for-the-antibacterial-drugs-market-due-to-escalating-government-initiatives-and-increasing-patient-population-tmr-insights-301333796.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector — such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.

Contact

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

0 notes

jesse-pinkman123 · 3 years ago

Text

Still’s Disease Treatment Market Size, Trends, Shares, Insights and Forecast – 2018-2026

Global Still’s Disease Treatment Market, by Treatment (Pain Management, Corticosteroids, Tocilizumab, Canakinumab, Anakinra, and Others), by Route of Administration (Injectable and Oral), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$1,539.4 million in 2020 and is expected to exhibit a CAGR of 4.49% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Still’s disease is a rare systemic inflammatory condition classified under polygenic autoinflammatory disorder. The condition is characterized by persistent high spiking fever, salmon colored skin rash, and arthralgia. Still’s disease is more commonly observed in infants, known as systemic-onset juvenile idiopathic arthritis (SOJIA) whereas, in adults, it is referred to as adult-onset Still’s disease (AOSD). However, there is no single diagnostic test available for Still’s disease. Diagnosis is typically done based on the observation of aforementioned symptoms. Also, the treatment option for this condition is selected based on the varying degree of symptoms.

Players in the market are focused on research & development, drug approvals, and launching them in the market, which is driving growth of the still’s disease treatment market. Moreover, companies are focused on partnerships and joint agreements for the development of novel therapies. For instance, in May 2019, Chugai Pharmaceutical Co., Ltd. received expanded drug approval for adult-onset Still's disease from the Ministry of Health Labor and Welfare in Japan for Actemra (tocilizumab). Actemra is used for Still’s disease treatment.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/4023

Similarly, in April 2018, Swedish Orphan Biovitrum AB received expanded approval from the European Commission (EC) for Kineret (anakinra), which is an interleukin-1 receptor antagonist for the treatment of Still’s Disease. Kineret was previously approved for rheumatoid arthritis treatment. This approval expanded indication of anakinra as well as addresses the significant unmet medical need among Still’s disease patient population. Such factors are expected to strongly support growth of the still’s disease treatment market.

Still’s Disease Treatment Market - Impact of Coronavirus (Covid-19) Pandemic

The COVID-19 outbreak has adversely affected the still’s disease treatment market growth. It has become difficult for the researchers to conduct researches during this COVID-19 pandemic. People with Still's disease are at more risk to get infected with the COVID-19 virus. Therefore, key players in this industry are focusing on developing strategies to help patients to remain agile during the global disruptions due to the pandemic crisis. Moreover, the government bodies of various countries are taking initiatives to deal with the current chaos.

Browse 26 Market Data Tables and 28 Figures spread through 140 Pages and in-depth TOC on Still’s Disease Treatment Market, By Treatment (Pain Management, Corticosteroids, Tocilizumab, Canakinumab, Anakinra, and Others), By Route of Administration (Injectable and Oral), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Forecast to 2027"

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/stills-disease-treatment-market-4023

The rise in funding for research & development to develop novel treatment and therapies is a major factor propelling growth of the global still’s disease treatment market. Moreover, the emergence of drugs for the complications related to adult-onset still’s disease treatment is another factor boosting the market growth. For instance, in June 2020, the U.S. Food and Drug Administration (FDA) approved the usage of Canakinumab (Ilaris) in active still’s disease.

Key Takeaways of the Global Still’s Disease Treatment Market:

The global still’s disease treatment market is expected to exhibit a CAGR of 4.49% during the forecast period (2020-2027), owing to collaborations and drug launches by market players

Among therapy types, corticosteroid segment accounted for significant revenue share in the global market. Corticosteroid therapy is started promptly with the dosage of 0.5–1 mg/kg/day, once the diagnosis is confirmed.

Major players operating in the global still’s disease treatment market include AB2 Bio Ltd., Jubilant Life Sciences Ltd, F. Hoffmann-La Roche Ltd, Swedish Orphan Biovitrum AB, Novartis AG, Vintage Labs, Teva Pharmaceutical Industries Ltd, Hikma Pharmaceuticals PLC, Mylan N.V., Sun Pharmaceutical Industries Ltd, Horizon Therapeutics plc, Zydus Cadila, Dr Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, and Fresenius Kabi AG.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/4023

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

mailto:[email protected]

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

#Still’s Disease Treatment Market Share #Still’s Disease Treatment Market

0 notes

digitalconvo · 4 years ago

Text

Insulin Biosimilars Market Detailed Analysis and Forecast 2018-2028

Global Insulin Biosimilars Market: Overview

It is just handful of companies that are into the distribution and manufacturing of most of the insulin used in the developed countries. A number of new market players have developed its insulin making capacities and such a development is based on the methods of modern biotechnology.

The global insulin biosimilars market gathers its momentum from the increasing prevalence of diabetes. According to a report of World Health Organization (WHO), around 422 Mn adults are suffering from diabetes and around 1.5 million people have been killed by diabetes in the 2012. Insulin biosimilar can improve the access to treatment of diabetes mellitus amongst the diabetic patients. It also lessens the cost of treatment.

The global insulin biosimilars market has been segmented on the basis of type, disease indication, and region. The main objective of providing such a comprehensive report is to provide a deep insight into the market.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6148

Global Insulin Biosimilars Market: Notable Developments

The global insulin biosimilars market has witnessed quite a few developments over the last few years. These market developments suggest a trend and give an idea about the growth factors of the global insulin biosimilars market. One such development is mentioned below:

In 2016, the U.S-based Momenta Pharmaceuticals, Inc. revealed that it has formed a global collaboration agreement with the US-based Mylan N.V. The collaboration is aimed at commercializing, manufacturing, and developing six of Momenta Pharmaceutical’s present biosimilar candidates. The collaboration also comprised ORENCIA, one of its prominent biosimilar candidates. It is used for the treatment of moderate to severe adult psoriatic arthritis, juvenile idiopathic arthritis, and adult rheumatoid arthritis.

Some of the key market players of the global insulin biosimilars market are

Eli Lilly and Company

H. Boehringer Sohn AG & Ko. KG

Novo Nordisk A/S

Wockhardt Ltd.

Momenta Pharmaceuticals, Inc.

Ypsomed AG

Global Insulin Biosimilars Market: Growth Drivers

Rapid Rise in the Prevalence of Diabetes Worldwide Accentuates its Demand

Biosimilar insulins are made in such a way that it remains extremely similar to the original product. With the rise in the number of biosimilar insulin manufacturers, the offering of clinical aid similar to the present analogs of insulin at a more reasonable price has become possible. In addition, many insulin manufacturing firms are likely to lose their patents quite soon, which is likely to offer ample growth opportunities for the global insulin biosimilars market.

Furthermore, low pricing of biosimilar insulin meant for the treatment of diabetes along with its effectiveness is anticipated to open up new vistas of growth for the global insulin biosimilars market. Several companies are emphasizing on the development of medical devices that enable less painful and self delivery of biosimilar insulin. Such a factor is expected to propel the growth of the global insulin biosimilars market.

Expanding pool of geriatric population with arthritis and growing demand for fast acting insulin analogues is another booster for the market. Increased investment by government agencies on the research and development activities pertaining to insulin biosimilars is providing ample scope of development for the market.

To get Incredible Discounts on this Report, Click Here @https://www.tmrresearch.com/sample/sample?flag=D&rep_id=6148

Global Insulin Biosimilars Market: Regional Outlook

In terms of region, the global insulin biosimilar market is split into the key regions of Middle East and Africa, North America, Europe, Asia Pacific, and Latin America. Of all the geographical segments, it is expected that North America will reign over the global insulin biosimilar market in the forthcoming years. High demand for insulin biosimilars amidst increasing prevalence of diabetes is likely to propel growth of the market in years to come.

Asia Pacific is prophesized to come up as a rapidly growing region in the market due to expanding pool of diabetic patients and changing lifestyle of the people. High competitiveness amongst the companies in the region is expected to further lower the price, thereby propelling the market toward growth.

The global insulin biosimilars market is segmented as:

Type

Rapid Acting Biosimilars

Long Acting Biosimilars

Premixed Biosimilars

Disease Indication

Type 1 Diabetes

Type 2 Diabetes

Request For TOC @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6148

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research, 3739 Balboa St # 1097, San Francisco, CA 94121 United States

Tel: +1-415-520-1050

0 notes

kunalcmi · 4 years ago

Text

STILL’S DISEASE TREATMENT MARKET ANALYSIS (2020-2027)

Still’s disease is a rare rheumatic condition. This condition is characterized by biological and clinical symptoms such as high spiking fever, joint swelling, muscle pain, sore throat, increased number of white cells (leukocytes, especially neutrophils), and biological hepatitis. Treatment for still’s disease can be classified into 2 categories, namely symptomatic treatments and effective therapies. Symptomatic treatments can be initiated immediately, even when the diagnosis has not been established whereas, effective therapies are designed to treat the condition more efficiently to eradicate the symptoms of the disease.

According to a study published in The American Journal of Medicine, the treatment of still’s disease has been largely derived from retrospective data and case reports. While mild cases can be treated with NSAIDs (Nonsteroidal Anti-inflammatory Drugs), more than 80% of still’s disease patients need the use of corticosteroids and do not achieve remission. There is no such known risk factor that develops the Still’s disease, however, it is assumed that it is caused due to over activation of IL-1 (Interleukin-1) in the body.

The rising demand for specific new treatments and the emergence of drugs for still’s disease are expected to drive the still’s disease treatment market growth during the forecast period. For instance, as per the U.S. Food and Drug Administration (FDA), Canakinumab (Ilaris) can be indicated to all patients older than 2 years with Still's disease.

Still’s Disease Treatment Market - Impact of Coronavirus (Covid-19) Pandemic

Still’s disease treatment market is hugely affected due to the outbreak of COVID-19, as it is becoming difficult for researchers to conduct researches during this pandemic situation. People with rheumatic diseases such as Still's disease are more prone to getting infected with the coronavirus. Thus, majority of the vendors are concentrating on developing strategies to help patients with still’s disease to remain agile during the global disruptions due to COVID-19 pandemic. In addition, many government bodies across the globe are taking decisions such as new regulations to deal with the current crisis.

The all-inclusive version of the report will include the impact of COVID-19 and the probable changes in the future outlook of the industry, by taking into account the technological, social, political, and economical parameters.

The still’s disease treatment market is estimated to be valued at US$ 1,539.4 million in 2020 and is expected to rise at a CAGR of 4.49% during the forecast period (2020-2027).

Figure 1. Still’s Disease Treatment Market Share (%) Analysis, By Route of Administration, 2020

An increase in the number of mergers & acquisitions and drug launches is expected to propel growth of the still’s disease treatment market

Key players in the market are involved in mergers & acquisitions to develop advanced drugs and treatment, and launch them in the still’s disease treatment market. The drug launches in the industry is estimated to significantly boost the market growth and create lucrative growth opportunities in the overall market during the forecast period.

For instance, in July 2018, SOBI launched a third-line treatment, Kineret drug for the treatment of adult-onset still's disease (AOSD). This new therapy is indicated when the patient does not respond to Disease-modifying antirheumatic drugs (DMARDs) and corticosteroids, and fail to respond to methotrexate. The drug is currently available in the U.K. for Cryopyrin-associated periodic syndromes (CAPS) and rheumatoid arthritis (RA).

Furthermore, companies are adopting several strategies such as license agreements and partnerships to hold a strong position in the global industry. For instance, in July 2019, Aevi Genomic Medicine entered into a license agreement with AstraZeneca for phase II trials of MEDI2338, which is a fully human mAb (monoclonal antibody) that targets IL-18 (interleukin 18). The company has planned to initially develop MEDI2338 for AOSD (adult-onset Still's disease), which is a rare and orphan rheumatological disease with presently no approved biologic therapies in the U.S.

Still’s Disease Treatment Market - Restraints

Unavailability of specific therapeutics for still’s disease condition is considered to be one of the potential restraints affecting the market growth. For instance, the treatment for still’s disease is directed towards the use of anti-inflammatory drugs such as aspirin and other nonsteroidal drugs (NSAIDs). In some cases, cortisone medications such as prednisone are used to treat the condition. Other factors such as increasing number of generic therapeutics, product recalls, and patent expiration of licenses & various drugs are likely to hamper the market growth.

Request Sample Free Copy of Report here: https://www.coherentmarketinsights.com/insight/request-sample/4023

Download PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/4023

Still’s Disease Treatment Market – Regional Analysis

Europe region accounted for the largest share in the still’s disease treatment market in 2019, owing to the increasing focus of key players on research & development and European Commission (EC) approvals in the market. For instance, in April 2018, Swedish Orphan Biovitrum AB announced that Kineret (anakinra) is approved by the EC for the treatment of still’s disease. Kineret is indicated for adults, children, adolescents, and infants aged 8 months and above with at least 10kg bodyweight for the treatment of Still’s disease. This also includes AOSD and SJIA with active systemic features of moderate to high disease activity.

The U.S. market followed the same. In June 2020, the U.S. FDA approved Switzerland-based Novartis’s Ilaris injection for the treatment of active still’s disease. This approval also includes treatment for Adult-Onset Still’s Disease (AOSD). The Ilaris injection was formerly approved for SJIA (Systemic Juvenile Idiopathic Arthritis) in patients aged 2 years and above.

The Asia Pacific region is witnessing a promising growth in the global still’s disease treatment market, owing to initiatives taken by key players and approvals for the treatment of adult still’s disease. For instance, in May 2019, Chugai Pharmaceutical Co., Ltd., a subsidiary of F. Hoffmann-La Roche Ltd. received expanded approval from the MHLA (Ministry of Health Labor and Welfare) in Japan for Actemra (tocilizumab) for the treatment of adult Still’s disease.

Figure 2. Still’s Disease Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027

Global Still’s Disease Treatment Market - Competitive Landscape

Key players operating in the Still’s disease treatment market include AB2 Bio Ltd., F. Hoffmann-La Roche Ltd, Novartis AG, Swedish Orphan Biovitrum AB, Jubilant Life Sciences Ltd, Vintage Labs, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd, Mylan N.V., Horizon Therapeutics plc, Sun Pharmaceutical Industries Ltd, Zydus Cadila, Amneal Pharmaceuticals LLC, Dr Reddy's Laboratories Ltd., and Fresenius Kabi AG.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

Email: [email protected]

Source: https://www.coherentmarketinsights.com/market-insight/stills-disease-treatment-market-4023

#Still’s Disease Treatment Market #CoherentMarketInsights #MarketResearch Industryanalysis #BusinessConsulting

0 notes

rohinic123-blog · 4 years ago

Text

Biosimilars Market Key Opportunities and Forecast up to 2027

Biosimilars Market: Introduction

Biosimilars can be defined as a biologic medical product, which is considered to be similar to already approved biologic. These biosimilars are approved based on their efficacy, quality, safety, and the same standards of pharmaceutical quality that apply to all biologic medicines. Chronic disease prevalence has been increasing significantly at the global level. This necessitates the need for affordable treatment, contributing to the growth of the biosimilars market.

Request For Covid19 Impact Analysis –

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=118

Europe dominated the biosimilars market in 2018 and the trend is anticipated to continue during the forecast period. The strong growth of the market in the region can be attributed to increase in approvals of biosimilars in Europe. For instance, in 2018, over 16 biosimilars were approved in the region for various indications, including oncology, chronic diseases, and autoimmune diseases.

Patent Expiry of Major Biologics to Accelerate Market Growth

Patent expiries of major biologics are expected to contribute to the growth of the biosimilars market.

For instance, the U.S. patent of MabThera/Rituxan (rituximab), a biologic manufactured by Roche, expired in 2016. This provides ample growth opportunities to manufacturers of rituximab biosimilar, such as Amgen, Boehringer Ingelheim, and Pfizer. In addition, a range of top selling brands including Herceptin, Enbrel, Humalog, and Aranesp are anticipated to lose patents during the forecast period.

Planning To Lay Down Future Strategy? Request Brochure Of Biosimilars Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=118

Increase in Approvals of Biosimilars to Drive Global Market

The U.S. has witnessed a wave of biosimilar approvals in 2019. According to the Antibody Society in the U.S., over 16 antibody biosimilar therapeutics were approved from 2015 to 2019. Drugs approved in 2019 include Trazimera, Kanjinti, and Ruxience.

As per the FDA’s Biosimilars Action Plan, new policies are being made to make the development of biosimilars more efficient and provide significant opportunities to biosimilar manufacturers. This is anticipated to propel the rate of biosimilar approvals in the U.S., contributing to the growth of the biosimilars market.

High Demand for Recombinant Non-glycosylated Protein Biosimilars

In terms of product, the recombinant non-glycosylated proteins segment is likely to account for a major share of the global biosimilars market. Moreover, the insulin sub-segment of the recombinant non-glycosylated proteins segment dominated the market in 2018. It is likely to grow at a high CAGR during the forecast period, due to increase in prevalence of diabetes globally. According to the International Diabetes Federation, over 463 million adults aged between 20 years and 79 years lived with diabetes in 2019.

To Obtain All-Inclusive Information On Forecast Analysis Of Biosimilars Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=118

Biosimilars for Oncology Indication to Dominate Global Market

In terms of indication, the global biosimilars market has been divided into chronic diseases, oncology, autoimmune diseases, infectious diseases, blood disorders, growth hormone deficiency, and others. The oncology segment held the largest market share in 2018 and the trend is anticipated to continue during the forecast period. The robust growth of the segment can be attributed to rise in prevalence of cancer cases globally. According to the World Cancer Research fund, over 18 million cancer cases were reported in 2018. In addition, the patent expiration of a range of cancer biologic drugs, leading to the growing usage of biosimilars, owing to their lower costs contributes to the growth of the segment in the forecast period.

Biosimilars Market: Prominent Regions

In terms of region, the global biosimilars market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Europe dominated the global biosimilars market in 2018. This can be attributed to the significant price reduction in biosimilars as compared to biologics, and country policies in Europe enabling the penetration of biosimilars to enhance patient access to affordable treatment, contributes to the growth of the market in Europe.

The biosimilars market in Asia Pacific is likely to expand at a rapid CAGR from 2019 to 2027. Increase in population of Asian countries, rise in urbanization, surge in aging population, lifestyle changes, and growing incidence of non-communicable diseases such as diabetes, cancer, and autoimmune diseases are driving the biosimilars market in Asia Pacific. Furthermore, various countries in South Asia have been assigning a major portion of their medical research budget for the development of biosimilars.

Biosimilars Market: Key Strategies

The global biosimilars market is consolidated in terms of number of players. Key players operating in the global biosimilars market include Pfizer, Inc., Intas Pharmaceuticals Ltd., Biocon, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (A Novartis Division), Celltrion Inc., Amgen, Inc., STADA Arzneimittel AG, and Apotex Inc. (Apobiologix).

These players have adopted various strategies such as product portfolio expansion, investment in research & development, collaborations, and product launches to establish a strong geographic presence. For instance, in November 2019, Pfizer received the U.S. FDA approval for its ABRILADA, a biosimilar to Humira, for the treatment of patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis, and plaque psoriasis.

More Trending Reports by Transparency Market Research –

Wheelchairs Market -

https://www.prnewswire.com/news-releases/wheelchairs-market-to-surpass-a-value-of-us-6-253-6-million-by-2026--says-tmr-300805704.html

Implantable Medical Devices Market -

https://www.biospace.com/article/implantable-medical-devices-market-rise-in-prevalence-of-coronary-arterial-diseases-cads-will-increase-industry-demand/

0 notes

sdmr123 · 5 years ago

Link

According to a study, over the next five years the Systemic Idiopathic Juvenile Arthritis Treatmentmarket will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2026, from US$ xx million in 2020. In particular, this report presents the global market share (sales and revenue) of key companies in Systemic Idiopathic Juvenile Arthritis Treatmentbusiness. Systemic Idiopathic Juvenile Arthritis Treatment market development trend, sales volume and sales value (million USD) forecast in regional market, the main regions are China, USA, Europe, India, Japan, Korea, South America, Southeast Asia.

To get a free sample report:https://www.supplydemandmarketresearch.com/home/contact/1034747?ref=Sample-and-Brochure&toccode=SDMRME1034747

To get a detailed report:https://www.supplydemandmarketresearch.com/global-systemic-idiopathic-juvenile-arthritis-treatment-sales-market-1034747

#Global Systemic Idiopathic Juvenile Arthritis Treatment Sales Market size #Global Systemic Idiopathic Juvenile Arthritis Treatment Sales Market research #Global Systemic Idiopathic Juvenile Arthritis Treatment Sales Market cost #v size #Global Systemic Idiopathic Juvenile Arthritis Treatment Sales Market report #Global Systemic Idiopathic Juvenile Arthritis Treatment Sales Market demand

0 notes

pranalipawarshinde · 3 years ago

Text

Biosimilar Market Research Insights Shared in Detailed Report Forecast 2019-2027

Biosimilars Market: Introduction

High Demand for Recombinant Non-glycosylated Protein Biosimilars

Request Brochure:

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=118

Biosimilars for Oncology Indication to Dominate Global Market

Biosimilars Market: Prominent Regions

Request for covid19 Impact Analysis:https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=118

Biosimilars Market: Key Strategies

· The global biosimilars market is consolidated in terms of number of players. Key players operating in the global biosimilars market include Pfizer, Inc., Intas Pharmaceuticals Ltd., Biocon, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (A Novartis Division), Celltrion Inc., Amgen, Inc., STADA Arzneimittel AG, and Apotex Inc. (Apobiologix).

· These players have adopted various strategies such as product portfolio expansion, investment in research & development, collaborations, and product launches to establish a strong geographic presence. For instance, in November 2019, Pfizer received the U.S. FDA approval for its ABRILADA, a biosimilar to Humira, for the treatment of patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis, and plaque psoriasis.

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/cardiovascular-proximal-anastomosis-devices-market-to-reach-us-23-6-mn-by-2030--says-tmr-report-301494327.html

https://www.prnewswire.com/news-releases/albumin-market-to-rise-at-cagr-of-6-2-during-forecast-period-observes-tmr-study-301500236.html

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants uses proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: [email protected]

Website: https://www.transparencymarketresearch.com/

0 notes